NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this month confirmed previous guidance on its two drug candidates, the solid tumor therapy DCR-MYC and the primary hyperoxaluria 1 (PH1) treatment DCR-PH1, stating that both agents remain on track to enter new clinical trials later this year and in 2015, respectively.

The newly minted public company also released its financial results for the second quarter, reporting higher losses amid increased research and development spending.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.